title: Activity of cisplatin in adenocarcinoma of the pancreas.
abstract: The activity of cisplatin in metastatic adenocarcinoma of the pancreas was assessed in 33 patients. Cisplatin was administered in a dose of 100 mg/m2, every 4 weeks. There were 2 complete responses and 5 partial responses (a response rate of 21%). The median duration of response was 5 months (range, 2+ to 15 months). Cisplatin is a modestly active drug in advanced pancreatic cancer.
authors.affiliation: Department of Oncology, Laurentius Hospital, Rotterdam, The Netherlands.
authors.forename: J A
authors.initials: JA
authors.lastname: Wils
authors.forename: T
authors.initials: T
authors.lastname: Kok
authors.forename: D J
authors.initials: DJ
authors.lastname: Wagener
authors.forename: J
authors.initials: J
authors.lastname: Selleslags
authors.forename: N
authors.initials: N
authors.lastname: Duez
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D002945:Cisplatin